Larissa Sandalic

629 total citations · 1 hit paper
13 papers, 403 citations indexed

About

Larissa Sandalic is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Larissa Sandalic has authored 13 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Larissa Sandalic's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Larissa Sandalic is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). Larissa Sandalic collaborates with scholars based in United States, Switzerland and Russia. Larissa Sandalic's co-authors include Laurie E. Grove, Eric L. Sievers, Brent L. Wood, Mikkael A. Sekeres, Joseph G. Jurcic, F. B. Oldham, Jack W. Singer, B. Bandstra, Felix Sahm and Uri Tabori and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Larissa Sandalic

13 papers receiving 398 citations

Hit Papers

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF ... 2023 2026 2024 2025 2023 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations
    2023 125 citations Éric Bouffet, Jordan R. Hansford et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larissa Sandalic United States 9 167 122 111 67 63 13 403
Zhengzi Qian China 10 179 1.1× 120 1.0× 89 0.8× 39 0.6× 197 3.1× 29 415
Jingxuan Liu United States 11 131 0.8× 235 1.9× 69 0.6× 43 0.6× 40 0.6× 39 572
PY Dietrich Switzerland 8 91 0.5× 92 0.8× 90 0.8× 79 1.2× 79 1.3× 13 380
Martin Bjerregård Pedersen Denmark 9 171 1.0× 65 0.5× 55 0.5× 36 0.5× 265 4.2× 25 438
Elena Ciabatti Italy 12 108 0.6× 98 0.8× 148 1.3× 159 2.4× 103 1.6× 39 437
Steven Park United States 14 282 1.7× 132 1.1× 121 1.1× 21 0.3× 227 3.6× 29 518
Jodi A. Muscal United States 13 142 0.9× 249 2.0× 75 0.7× 41 0.6× 40 0.6× 27 469
Yang Xun China 12 100 0.6× 192 1.6× 51 0.5× 42 0.6× 41 0.7× 38 499
Mark Bustoros United States 10 80 0.5× 170 1.4× 77 0.7× 120 1.8× 38 0.6× 21 299
Thuy Trinh Germany 11 147 0.9× 194 1.6× 167 1.5× 31 0.5× 19 0.3× 20 501

Countries citing papers authored by Larissa Sandalic

Since Specialization
Citations

This map shows the geographic impact of Larissa Sandalic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larissa Sandalic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larissa Sandalic more than expected).

Fields of papers citing papers by Larissa Sandalic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larissa Sandalic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larissa Sandalic. The network helps show where Larissa Sandalic may publish in the future.

Co-authorship network of co-authors of Larissa Sandalic

This figure shows the co-authorship network connecting the top 25 collaborators of Larissa Sandalic. A scholar is included among the top collaborators of Larissa Sandalic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larissa Sandalic. Larissa Sandalic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Bouffet, Éric, Jordan R. Hansford, Maria Luisa Garrè, et al.. (2023). Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. New England Journal of Medicine. 389(12). 1108–1120. 125 indexed citations breakdown →
2.
LoRusso, Patricia, Marwan Fakih, Filip De Vos, et al.. (2020). 561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours. Annals of Oncology. 31. S484–S484. 5 indexed citations
3.
Brossard, Patrick, Larissa Sandalic, Mikael Franzon, et al.. (2017). Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Delivery System. Nicotine & Tobacco Research. 20(4). 458–465. 8 indexed citations
4.
Broglio, Kristine, Larissa Sandalic, Tina Albertson, & Scott Berry. (2015). Bayesian dose escalation in oncology with sharing of information between patient populations. Contemporary Clinical Trials. 44. 56–63. 5 indexed citations
5.
Fathi, Amir T., Robert Chen, Tanya Trippett, et al.. (2014). Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Blood. 124(21). 963–963. 25 indexed citations
6.
Moskowitz, Craig H., Andres Forero‐Torres, Bijal Shah, et al.. (2014). Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. Blood. 124(21). 1741–1741. 16 indexed citations
7.
Forero‐Torres, Andres, Craig H. Moskowitz, Ranjana H. Advani, et al.. (2014). Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 32(15_suppl). 8505–8505. 12 indexed citations
8.
Borate, Uma, Amir T. Fathi, Bijal Shah, et al.. (2013). A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Blood. 122(21). 1437–1437. 13 indexed citations
9.
Sekeres, Mikkael A., Brent L. Wood, Laurie E. Grove, et al.. (2012). Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 98(1). 119–128. 72 indexed citations
10.
11.
12.
13.
Ross, Helen J., F. B. Oldham, B. Bandstra, et al.. (2007). Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naive advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2. Journal of Clinical Oncology. 25(18_suppl). 7683–7683. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhengzi Qian Breakdown of academic impact, for papers by Jingxuan Liu Breakdown of academic impact, for papers by PY Dietrich Breakdown of academic impact, for papers by Martin Bjerregård Pedersen Breakdown of academic impact, for papers by Elena Ciabatti Breakdown of academic impact, for papers by Steven Park Breakdown of academic impact, for papers by Jodi A. Muscal Breakdown of academic impact, for papers by Yang Xun Breakdown of academic impact, for papers by Mark Bustoros Breakdown of academic impact, for papers by Thuy Trinh
Rankless by CCL
2026